ReviewJournal of bone oncology2025
Application of responsive nano-drug carriers in bone tumor chemotherapy.
Review in Journal of bone oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone tumors, especially malignant ones, have high mortality and disability rates, and traditional treatment methods have limitations. Responsive nano-drug carriers achieve targeted delivery and controlled release of drugs by precisely responding to the tumor microenvironment or external stimuli, thereby improving drug efficacy and reducing toxic side effects. These carriers, including liposomes, micelles, and nano-gels, can respond to internal stimuli such as pH, redox, enzymes, and hypoxia, as well as external stimuli such as light, magnetic fields, and ultrasound. By optimizing carrier design, significant improvements in drug targeting, bioavailability, and therapeutic effects can be achieved, providing new ideas and methods for the comprehensive treatment of bone tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.